Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 117Squamous Cell Carcinoma of Head and Neck 61Triple Negative Breast Neoplasms 55Melanoma 54Lung Neoplasms 49Neoplasm Metastasis 47Breast Neoplasms 42Neoplasms 38Colorectal Neoplasms 37Head and Neck Neoplasms 26Endometrial Neoplasms 25Carcinoma, Renal Cell 25Ovarian Neoplasms 22Uterine Cervical Neoplasms 21Stomach Neoplasms 21Carcinoma, Transitional Cell 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 19Recurrence 16Esophageal Neoplasms 16Pancreatic Neoplasms 15Carcinoma, Hepatocellular 14Sarcoma 12Glioblastoma 12Carcinoma, Squamous Cell 12Prostatic Neoplasms 11Esophageal Squamous Cell Carcinoma 11Carcinoma 11Brain Neoplasms 10Carcinoma, Merkel Cell 9

Interventions

Radiotherapy 2tislelizumab 1pembrolizumab 1TP protocol 1Paclitaxel 1Lomustine 1Cisplatin 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Neoplasm Recurrence, Local × pembrolizumab × Clear all
NCT06912087 2025-12-02

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

University of Chicago

Phase 1 Recruiting
36 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡